Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Donanemab in Early Alzheimer's Disease
Mark A. Mintun et al.
Summary: In this study, donanemab showed improved composite scores for cognition and daily living activities compared to placebo in patients with early Alzheimer's disease at 76 weeks, although secondary outcomes varied. Longer and larger trials are needed to further explore the efficacy and safety of donanemab in Alzheimer's disease.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Editorial Material
Medicine, General & Internal
A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab
Ezekiel J. Emanuel
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Editorial Material
Medicine, General & Internal
Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective
Billy Dunn et al.
JAMA INTERNAL MEDICINE (2021)
Share Paper
